

Please make the following changes to the application.


In the Claims:

Please cancel claims 1 through 10, 20 through 29, and 71 through 83.

Please amend and add the following claims:

11. (Amended) A pharmaceutical composition comprising:
- (a) a therapeutically effective amount of a combination of amlodipine and an atorvastatin compound selected from the group consisting of atorvastatin and hydroxylated atorvastatin metabolite; and
 - (b) one or more pharmaceutically acceptable formulation agents wherein said pharmaceutical composition synergistically lowers blood pressure and systemic lipid concentrations at least partially as a result of a synergistic inhibition of cholesterol crystal formation and a synergistic increase in nitric oxide production.
39. (Amended) A method of synergistically inhibiting cholesterol crystal formation comprising administering a therapeutically effective amount of a combination of amlodipine and an atorvastatin compound selected from the group consisting of atorvastatin and hydroxylated atorvastatin metabolite, wherein said inhibition of cholesterol formation is at least partially a result of a synergistic increase in nitric oxide production.
61. (Amended) A method of treating arterial and related heart disease comprising administering a therapeutically effective amount of a combination of amlodipine and an atorvastatin compound selected from the group consisting of atorvastatin and hydroxylated atorvastatin metabolite, wherein said method of treating arterial and related heart disease is at least partially a result of a synergistic increase in nitric oxide production.
- ⁶⁵
84. (New) The method of any of claims 61 through 70 wherein the treatment of arterial and related heart disease is at least partially a result of a process selected from the group consisting of reduced lipid oxidation and inhibited cholesterol crystal formation.

Clean Claims



11. (Amended) A pharmaceutical composition comprising:

(a) a therapeutically effective amount of a combination of amlodipine and an atorvastatin compound selected from the group consisting of atorvastatin and hydroxylated atorvastatin metabolite; and

(b) one or more pharmaceutically acceptable formulation agents wherein said pharmaceutical composition synergistically lowers blood pressure and systemic lipid concentrations at least partially as a result of a synergistic inhibition of cholesterol crystal formation and a synergistic increase in nitric oxide production.

39. (Amended) A method of synergistically inhibiting cholesterol crystal formation comprising administering a therapeutically effective amount of a combination of amlodipine and an atorvastatin compound selected from the group consisting of atorvastatin and hydroxylated atorvastatin metabolite, wherein said inhibition of cholesterol formation is at least partially a result of a synergistic increase in nitric oxide production.

61. (Amended) A method of treating arterial and related heart disease comprising administering a therapeutically effective amount of a combination of amlodipine and an atorvastatin compound selected from the group consisting of atorvastatin and hydroxylated atorvastatin metabolite, wherein said method of treating arterial and related heart disease is at least partially a result of a synergistic increase in nitric oxide production.

85
84. (New) The method of any of claims 61 through 70 wherein the treatment of arterial and related heart disease is at least partially a result of a process selected from the group consisting of reduced lipid oxidation and inhibited cholesterol crystal formation.